Patents by Inventor Zhenhua Sun

Zhenhua Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240131168
    Abstract: Anaphthalene ring-containing compound, a pharmaceutical composition containing same, and the use thereof. A naphthalene ring-containing compound as represented by formula III, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The compound is new in structure and has a better activity on cancers.
    Type: Application
    Filed: November 9, 2023
    Publication date: April 25, 2024
    Inventors: Liang WU, Yijun DENG, Zhenhua HE, Qiaoling SUN, Chen ZHOU, Tielin WANG
  • Patent number: 11786609
    Abstract: The present disclosure belongs to the technical field of gene therapy, and specifically relates to a series of lipid compounds as well as lipid vectors, nucleic acid lipid nanoparticle compositions, and pharmaceutical preparations containing the same. The compound having the structure of formula (I) provided by the present disclosure may be used in combination with other lipid compounds to prepare a lipid vector, which exhibits pH responsiveness, has high encapsulation efficiency for nucleic acid drugs, and greatly enhances the in-vivo delivery efficiency of nucleic acid drugs. Moreover, it is possible to select lipid compounds with different structures as lipid vectors to adjust the enrichment of nucleic acid drugs in different organs, thereby having good market application prospect.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: October 17, 2023
    Assignee: PURECODON (HONG KONG) BIOPHARMA LIMITED
    Inventors: Ke Huang, Chaoxuan Jing, Yingwen Li, Yinjia Gao, Yuping Liu, Zhenhua Sun
  • Publication number: 20230279389
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule and an application thereof in preparation of a circular RNA, and in particular, to a recombinant nucleic acid molecule for preparing a circular RNA, a recombinant expression vector, a circular RNA, a composition, a method for preparing a circular RNA, a method for expressing a target polypeptide in a cell, a method for screening a target coding region sequence, a system for screening a target coding region sequence, and a method for screening a ribozyme recognition site sequence.
    Type: Application
    Filed: July 22, 2022
    Publication date: September 7, 2023
    Inventors: Zonghao QIU, Qiangbo HOU, Yang ZHAO, Chijian ZUO, Zhenhua SUN
  • Publication number: 20230279407
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule based on point mutation of translation initiation element and use thereof in the preparation of circular RNA, and in particular to a recombinant nucleic acid molecule for preparing circular RNA, a recombinant expression vector, circular RNA, a composition, a method for preparing circular RNA, a method for expressing a target polypeptide in a cell, a method for preventing or treating a disease, a method for editing a translation initiation element sequence, and a system for editing a translation initiation element sequence.
    Type: Application
    Filed: July 22, 2022
    Publication date: September 7, 2023
    Inventors: Qiangbo HOU, Zonghao QIU, Yang ZHAO, Chijian ZUO, Zhenhua SUN
  • Patent number: 11690922
    Abstract: The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: July 4, 2023
    Assignee: Purecodon (Hong Kong) Biopharma Ltd.
    Inventors: Ke Huang, Binxi Ge, Yingwen Li, Yuping Liu, Yinjia Gao, Zhenhua Sun
  • Publication number: 20230173075
    Abstract: Compounds encapsulated with octenylsuccinic anhydride modified starch and methods of forming the encapsulated compounds are provided. Poorly water-soluble compounds, especially pharmaceuticals, are solubilized within an oil phase, which is then formed into an emulsion with an aqueous phase comprising the OSA modified starch. The resulting emulsion can be dried, such as through spray drying, for form a powder comprising the encapsulated compound.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 8, 2023
    Inventors: Yong-Cheng Shi, Zhenhua Sun
  • Patent number: 11634727
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA and its application in protein expression. Specifically, the present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA, recombinant expression vector, pre-circularized RNA, circular RNA, recombinant host cell, pharmaceutical composition and protein preparing method. The transcription product of the recombinant nucleic acid molecule in this present disclosure is a circular RNA which containing specific IRES element. IRES element can increase the protein expression level of circular RNA in eukaryotic cells, achieve efficient and persistent expression of protein. It has important application value in many fields like: Preparation of mRNA infectious disease vaccines, therapeutic mRNA tumor vaccines, mRNA-based dendritic cell tumor vaccines, mRNA-based gene therapy, mRNA-based chimeric antigen receptor T cell therapy, and protein supplement therapy.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: April 25, 2023
    Assignee: Purecodon (Hong Kong) Biopharma Ltd.
    Inventors: Zhenhua Sun, Chijian Zuo, Jiafeng Zhu
  • Publication number: 20230119715
    Abstract: The disclosure belongs to the technical field of bioinformatics and bioengineering, and specifically, relates to a Levenshtein distance-based IRES screening method, a polynucleotide screened based on this method, a circular nucleic acid molecule including the polynucleotide, a cyclization precursor nucleic acid molecule, a recombinant nucleic acid molecule, a recombinant expression vector, a recombinant host cell, and use. In the disclosure, averages of Levenshtein distances between all sample sequences and to-be-predicted sequences are compared, to efficiently and accurately determine whether there is an IRES in the to-be-predicted sequence, which has advantages of high efficiency and an accurate screening result.
    Type: Application
    Filed: October 12, 2022
    Publication date: April 20, 2023
    Inventors: Qiangbo HOU, Jiafeng ZHU, Zonghao QIU, Chijian ZUO, Zhenhua SUN
  • Patent number: 11629084
    Abstract: The present disclosure provides a solid waste treatment method, including following steps: screening off masses having a particle size greater than 0.5 cm from solid waste; adding extraction agents to the solid waste and then heating and stirring so that the solid waste is fully dispersed in the extraction agents; placing the mixed extraction agent in a centrifuge and centrifuging the mixed extraction feeding liquid phase separated by centrifuging into a rectification tower for rectification and cooling, recovering residual oil substances in a rectification kettle, separating mixture of cooled extraction agents and water, continuously adding the separated extraction agents into an extraction kettle for cyclic extraction, and conveying sewage to a sewage treatment plant to treat and discharging the sewage after the sewage reaches a treatment standard.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: April 18, 2023
    Assignee: CHINA UNIVERSITY OF PETROLEUM BLUE SKY(QINGDAO) PETROLEUM TECHNOLOGY CO., LTD
    Inventors: Weizhong Wei, Zhe Bai, Xinran Li, Haotian Gong, Rongguang Wu, Chuansheng Jia, Biao Yang, Deliang Liu, Zhenhua Sun
  • Publication number: 20230093138
    Abstract: The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.
    Type: Application
    Filed: July 21, 2022
    Publication date: March 23, 2023
    Inventors: Ke HUANG, Binxi GE, Yingwen LI, Yuping LIU, Yinjia GAO, Zhenhua SUN
  • Publication number: 20230060661
    Abstract: The present disclosure belongs to the technical field of bio-medicine, particularly, the present disclosure relates to a tissue-specifically expressed circular RNA molecule, a cyclization precursor RNA molecule, a recombinant nucleic acid molecule, a recombinant expression vector, a recombinant host cell, a composition, a pharmaceutical preparation and application thereof in preparation of a drug for preventing or treating diseases, as well as a method for preventing or treating diseases. The circular RNA molecule provided by the present disclosure operably links a coding region to an expression regulatory element, realizing specific high expression of a target polypeptide in target cells or target tissues, and low expression of the target polypeptide in non-target cells or non-target tissues, and having high tissue expression specificity, thereby providing a safe and effective treatment strategy for clinical targeted therapy of diseases such as tumors.
    Type: Application
    Filed: August 10, 2022
    Publication date: March 2, 2023
    Inventors: Chijian ZUO, Zonghao QIU, Jiali YANG, Jiafeng ZHU, Na LI, Zhenhua SUN
  • Publication number: 20230042694
    Abstract: The present disclosure belongs to the field of biomedicine. Specifically, the present disclosure relates to a circular RNA molecule, a cyclization precursor RNA molecule, a recombinant nucleic acid molecule, a recombinant expression vector, a recombinant host cell, a composition and use thereof in targeted degradation of a protein of interest, as well as a method for preventing or treating a disease. The circular RNA molecule has good membrane permeability, is easily delivered into cells, and has high-efficiency in vivo protein targeted degradation activity. The circular RNA molecule of the present disclosure successfully achieves inhibition of tumor growth, which proves the in vivo protein degradation activity of bio-PROTACs for the first time, and provides a positive and effective treatment solution for the treatment of diseases such as tumor.
    Type: Application
    Filed: July 26, 2022
    Publication date: February 9, 2023
    Inventors: Chijian ZUO, Jiali YANG, Jiafeng ZHU, Yaran DU, Yang ZHAO, Zhenhua SUN
  • Publication number: 20220378938
    Abstract: The present disclosure belongs to the technical field of gene therapy, and specifically relates to a series of lipid compounds as well as lipid vectors, nucleic acid lipid nanoparticle compositions, and pharmaceutical preparations containing the same. The compound having the structure of formula (I) provided by the present disclosure may be used in combination with other lipid compounds to prepare a lipid vector, which exhibits pH responsiveness, has high encapsulation efficiency for nucleic acid drugs, and greatly enhances the in-vivo delivery efficiency of nucleic acid drugs. Moreover, it is possible to select lipid compounds with different structures as lipid vectors to adjust the enrichment of nucleic acid drugs in different organs, thereby having good market application prospect.
    Type: Application
    Filed: July 26, 2022
    Publication date: December 1, 2022
    Inventors: Ke HUANG, Chaoxuan JING, Yingwen LI, Yinjia GAO, Yuping LIU, Zhenhua SUN
  • Publication number: 20220268393
    Abstract: A device to inspect a pipeline includes a device housing movable relative to the pipeline, a radiation device, and an imaging device. The radiation device is coupled to the device housing and disposed adjacent to the pipeline. The imaging device is coupled to the device housing and disposed adjacent to the pipeline. The imaging device is disposed opposite to the radiation device relative to the pipeline. The imaging device receives radiation from the radiation device to provide an imaging signal. Because the radiation device and the imaging device are disposed opposite to each other relative to the pipeline, the pipeline inspection device can provide an enhanced image in a single pass of the pipeline.
    Type: Application
    Filed: January 13, 2022
    Publication date: August 25, 2022
    Applicant: Kakivik Asset Management, LLC
    Inventors: Ian Moreau, Zhenhua Sun
  • Publication number: 20220268392
    Abstract: A device to inspect a pipeline includes a device housing, a plurality of motors, a plurality of wheels, an inertial measurement unit, and a controller. The plurality of motors is coupled to the device housing. The plurality of wheels extends from the device housing. Each wheel is rotatably coupled to a respective motor. The inertial measurement unit is configured to provide a signal corresponding to an orientation of the device housing relative to the pipeline. The controller is configured to independently control operation of each motor of the plurality of motors based on the signal provided by the inertial measurement unit to maintain the device housing within a desired orientation range relative to the pipeline. Because the controller can independently control each motor of the device, the device can advance along a pipeline with minimal human intervention.
    Type: Application
    Filed: August 27, 2021
    Publication date: August 25, 2022
    Applicant: Kakivik Asset Management, LLC
    Inventors: Ian Moreau, Zhenhua Sun
  • Patent number: 11404994
    Abstract: A frequency converter module includes a frequency control management module. An input port of the frequency conversion control management module is electrically connected to an input port of a power supply module. The power accuracy monitoring module includes an initial power measuring module, a power prediction correction module, and an actual power display storage module. An output port of the initial power measuring module is electrically connected to an input port of the power prediction correction module. An output port of the power prediction correction module is electrically connected to an input port of the actual power display storage module.
    Type: Grant
    Filed: December 25, 2020
    Date of Patent: August 2, 2022
    Assignee: CHINA UNIVERSITY OF PETROLEUM BLUE SKY(QINGDAO) PETROLEUM TECHNOLOGY CO., LTD
    Inventors: Zhihao Wei, Tao Ding, Hongming Wang, Changfeng Wang, Haotian Gong, Zhongxian Gao, Zhenhua Sun, Huidong Lu, Xinran Li, Jiasheng Zhang
  • Publication number: 20220177908
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA and its application in protein expression. Specifically, the present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA, recombinant expression vector, pre-circularized RNA, circular RNA, recombinant host cell, pharmaceutical composition and protein preparing method. The transcription product of the recombinant nucleic acid molecule in this present disclosure is a circular RNA which containing specific IRES element. IRES element can increase the protein expression level of circular RNA in eukaryotic cells, achieve efficient and persistent expression of protein. It has important application value in many fields like: Preparation of mRNA infectious disease vaccines, therapeutic mRNA tumor vaccines, mRNA-based dendritic cell tumor vaccines, mRNA-based gene therapy, mRNA-based chimeric antigen receptor T cell therapy, and protein supplement therapy.
    Type: Application
    Filed: June 3, 2021
    Publication date: June 9, 2022
    Inventors: Zhenhua SUN, Chijian ZUO, Jiafeng ZHU
  • Publication number: 20220177910
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA and its application in protein expression. Specifically, the present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA, recombinant expression vector, pre-circularized RNA, circular RNA, recombinant host cell, pharmaceutical composition and protein preparing method. The transcription product of the recombinant nucleic acid molecule in this present disclosure is a circular RNA which containing specific IRES element. IRES element can increase the protein expression level of circular RNA in eukaryotic cells, achieve efficient and persistent expression of protein. It has important application value in many fields like: Preparation of mRNA infectious disease vaccines, therapeutic mRNA tumor vaccines, mRNA-based dendritic cell tumor vaccines, mRNA-based gene therapy, mRNA-based chimeric antigen receptor T cell therapy, and protein supplement therapy.
    Type: Application
    Filed: September 27, 2021
    Publication date: June 9, 2022
    Inventors: Zhenhua SUN, Chijian ZUO, Jiafeng ZHU
  • Publication number: 20220094174
    Abstract: Disclosed herein are multi-source microgrid power supply systems including a rectifier having an incoming line terminal connected to a low-voltage side of a transformer and an outgoing line terminal connected to a DC bus having one terminal connected to the outgoing line terminal of the rectifier, an inverter having an incoming line terminal connected to the DC bus and an outgoing line terminal connected to oil well equipment, a first voltage regulator having an incoming line terminal connected to a photovoltaic array and an outgoing line terminal connected to the DC bus, a second voltage regulator having an incoming line terminal connected to an energy storage unit and an outgoing line terminal connected to the DC bus, and a third voltage regulator having an incoming line terminal connected to a wind power generation unit and an outgoing line terminal connected to the DC bus.
    Type: Application
    Filed: September 21, 2020
    Publication date: March 24, 2022
    Applicant: CHINA UNIVERSITY OF PETROLEUM BLUE SKY(QINGDAO) PETROLEUM TECHNOLOGY CO.,LTD
    Inventors: Weizhong WEI, Yulin LIU, Jiasheng ZHANG, Hongbo LI, Zhenhua SUN, Enfang XU, Zhongxian GAO, Xiaobo LIU, Jin HE
  • Patent number: 11208499
    Abstract: Water soluble, lipophilic starches are provided, which comprise a mixture of functionalized high and low molecular weight maltodextrin molecules. The starches may be formed by dispersing a granular starch in a liquid medium to form a slurry that is simultaneously cooked and subjected to enzyme hydrolysis. Following hydrolysis, the starch is functionalized with an organic acid anhydride reagent, such as octenylsuccinic anhydride. The organic acid anhydride substitution occurs randomly and at various locations within the maltodextrin molecules.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: December 28, 2021
    Assignee: Kansas State University Research Foundation
    Inventors: Yong-Cheng Shi, Yanjie Bai, Zhenhua Sun